Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD TNO155 - SHP2 inhibitor Study Indication Phase Patients Primary Outcome Measures NCT03114319 (CTNO155X2101) Solid tumors (single agent) Phase 1 255 Number of participants with adverse events Number of participants with dose limiting toxicities Arms Intervention Drug: TNO155 Drug: TNO155 in combination with EGF816 (nazartinib) Adult patients with advanced solid tumors in selected indications Target Patients Read-out Milesstone(s) 2023 Publication TBD 109 Investor Relations | Q3 2021 Results NCT04000529 (CTNO155B12101) Solid tumors (combo) Phase 1 126 Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment Dose tolerability TNO155 and Spartalizumab (PDR001) TNO155 and Ribociclib (LEE011) Patients with advanced malignancies 2022 TBD NOVARTIS | Reimagining Medicine

View entire presentation